abstract |
FIELD: medicine. n SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and may be used for treating dry age-related macular degeneration (dry ARMD). That is ensured by preparing a biocompatible prolonged release drug delivery system containing bevacizumab from 5 mcg to 20 mcg, and a carrier made of a polymer hyaluronic acid associated with bevacizumab administered into a vitreous body with using a 25-30-measuring syringe. In average, bevacizumab from 14 to 120 ng is released for 24 hours in the period of three to six months. The delivery system has a viscosity of 130,000 cPs to 300,000 cPs at the shear velocity of 0.1/second at 25°C. n EFFECT: using the given inventions enables treating dry ARMD with preventing or delaying wet ARMD. n 5 cl, 1 dwg, 3 ex |